2022
DOI: 10.1186/s12935-022-02781-x
|View full text |Cite
|
Sign up to set email alerts
|

Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance

Abstract: Background Tumor suppressor CYLD dysfunction by loss of its expression, triggers malignant transformation, especially drug resistance and tumor invasion/metastasis. Although loss of CYLD expression is significantly associated with poor prognosis in a large variety of tumors, no clinically-effective treatment for CYLD-negative cancer patients is available. Methods We focused on oral squamous cell carcinoma (OSCC), and sought to develop novel therape… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 70 publications
0
1
0
Order By: Relevance
“…Gefitinib is one of the most promising therapeutic agents targeting EGFR in OSCC [ 61 ]. It was also recently shown to improve prognosis in chemoresistant CYLD negative OSCC patients [ 62 ].…”
Section: Discussionmentioning
confidence: 99%
“…Gefitinib is one of the most promising therapeutic agents targeting EGFR in OSCC [ 61 ]. It was also recently shown to improve prognosis in chemoresistant CYLD negative OSCC patients [ 62 ].…”
Section: Discussionmentioning
confidence: 99%